Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Scharnhorst

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Clinica Chimica Acta; International Journal of Clinical Chemistry|December 7, 2018
A value proposition for trough level-based anti-TNFα drug dosingV Scharnhorst, E M H Schmitz, D van de Kerkhof, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|July 1, 2015
Urine flow cytometry can rule out urinary tract infection, but cannot identify bacterial morphologies correctlyN Geerts, A R Jansz, K J M Boonen, et al.
Oncogene|March 4, 2000
EGR-1 enhances tumor growth and modulates the effect of the Wilms' tumor 1 gene products on tumorigenicityV Scharnhorst, A L Menke, J Attema, et al.
Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation|August 31, 2016
Reduced number of cardiovascular events and increased cost-effectiveness by genotype-guided antiplatelet therapy in patients undergoing percutaneous coronary interventions in the NetherlandsB A L M Deiman, P A L Tonino, K Kouhestani, et al.
Clinical Rheumatology|June 9, 2017
Therapeutic drug monitoring (TDM) as a tool in the switch from infliximab innovator to biosimilar in rheumatic patients: results of a 12-month observational prospective cohort studyE M H Schmitz, S Benoy-De Keuster, A J L Meier, et al.
Journal of Critical Care|February 23, 2021
Increased sodium intake and decreased sodium excretion in ICU-acquired hypernatremia: A prospective cohort studyE H J Mestrom, J A van der Stam, M E Te Pas, et al.
Alimentary Pharmacology & Therapeutics|December 6, 2017
Switching from infliximab innovator to biosimilar in patients with inflammatory bowel disease: a 12-month multicentre observational prospective cohort studyE M H Schmitz, P J Boekema, J W A Straathof, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Clinica Chimica Acta; International Journal of Clinical Chemistry|December 7, 2018
A value proposition for trough level-based anti-TNFα drug dosingV Scharnhorst, E M H Schmitz, D van de Kerkhof, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|July 1, 2015
Urine flow cytometry can rule out urinary tract infection, but cannot identify bacterial morphologies correctlyN Geerts, A R Jansz, K J M Boonen, et al.
Oncogene|March 4, 2000
EGR-1 enhances tumor growth and modulates the effect of the Wilms' tumor 1 gene products on tumorigenicityV Scharnhorst, A L Menke, J Attema, et al.
Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation|August 31, 2016
Reduced number of cardiovascular events and increased cost-effectiveness by genotype-guided antiplatelet therapy in patients undergoing percutaneous coronary interventions in the NetherlandsB A L M Deiman, P A L Tonino, K Kouhestani, et al.
Clinical Rheumatology|June 9, 2017
Therapeutic drug monitoring (TDM) as a tool in the switch from infliximab innovator to biosimilar in rheumatic patients: results of a 12-month observational prospective cohort studyE M H Schmitz, S Benoy-De Keuster, A J L Meier, et al.
Journal of Critical Care|February 23, 2021
Increased sodium intake and decreased sodium excretion in ICU-acquired hypernatremia: A prospective cohort studyE H J Mestrom, J A van der Stam, M E Te Pas, et al.
Alimentary Pharmacology & Therapeutics|December 6, 2017
Switching from infliximab innovator to biosimilar in patients with inflammatory bowel disease: a 12-month multicentre observational prospective cohort studyE M H Schmitz, P J Boekema, J W A Straathof, et al.
Pageof 2